Compare BridgeBio Pharma Inc (BBIO) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Gold Fields Limited — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Gold Fields Limited trades at $32.72 (market cap $29.97B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays a 6.96% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GFI | |
|---|---|---|
Market Cap | $16.46B | $29.97B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $61.52 |
52-Week Low | $44.81 | $23.95 |
Enterprise Value | $18.02B | $31.41B |
Dividend Yield | — | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Gold Fields (GFI) trades at $33.53, down 1.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 8.51, net income margin of 40.76%, and robust ROE of 52.33%. Recent earnings were mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and revenue growth accelerated to $8.8B. Analyst consensus is a Buy with a $52.75 price target, though recent news highlights operational cost pressures.
The outlook for GFI is positive based on valuation and profitability, but near-term risks include cost inflation and gold price volatility. The stock offers value with upside to analyst targets, supported by strong cash generation and a shareholder-friendly dividend policy. Key risks are execution at mines and macroeconomic factors affecting gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
